التفاصيل البيبلوغرافية
| العنوان: |
Standalone Lab-on-a-Chip Systems toward the Evaluation of Therapeutic Biomaterials in Individualized Disease Treatment. |
| المؤلفون: |
Tng DJH; School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798., Song P; School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798., Hu R; School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798., Yang C; School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798., Tan CH; Department of Diagnostic Radiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433., Yong KT; School of Electrical and Electronic Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798. |
| المصدر: |
ACS biomaterials science & engineering [ACS Biomater Sci Eng] 2015 Nov 09; Vol. 1 (11), pp. 1055-1066. Date of Electronic Publication: 2015 Sep 24. |
| نوع المنشور: |
Journal Article |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: American Chemical Society Country of Publication: United States NLM ID: 101654670 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2373-9878 (Electronic) Linking ISSN: 23739878 NLM ISO Abbreviation: ACS Biomater Sci Eng Subsets: PubMed not MEDLINE; MEDLINE |
| أسماء مطبوعة: |
Original Publication: Washington, DC : American Chemical Society, [2015]- |
| مستخلص: |
As each tumor is unique, treatments should be individualized in terms of their drug formulation and time dependent dosing. In vitro lab-on-a-chip (LOC) drug testing is a viable avenue to individualize treatments. A drug testing platform in the form of a customizable standalone LOC system is proposed for treatment individualization in vitro. The platform was used to individualize the treatment of pancreatic cancer by using PANC-1 and MIA PaCa-2 cell lines cultured on-chip. Using on-chip drug uptake, growth, and migration inhibition assays, the therapeutic effect of various treatment combinations was analyzed. Thereafter, optimized treatments were devised for each cell line. The individualized dosage for MIA PaCa-2 cell line was found to be between 0.05-0.1 μg/μL of doxorubicin (DOX), where the greatest growth and migration inhibition effects were observed. As the PANC-1 cell line showed resistance to DOX only formulations, a multidrug approach was used for individualized treatment. Compared to the DOX only formulations, the individualized treatment produced the same degree of migration inhibition but with 5-10 times lower concentration of DOX, potentially minimizing the side-effects of the treatment. Furthermore, the individualized treatment had an average of 672.4% higher rate of growth inhibition. Finally, a preliminary study showed how a tested formulation from the LOC system can be translated for use by employing a nanoparticle system for controlled delivery, producing similar therapeutic effects. The use of such systems in clinical practice could potentially revolutionize treatment formulation by maximizing the therapeutic effects of existing treatments while minimizing their potential side effects through individualization of treatment. |
| فهرسة مساهمة: |
Keywords: biocompatible; electrochemical; individualized; lab-on-a-chip; standalone |
| تواريخ الأحداث: |
Date Created: 20210112 Latest Revision: 20210112 |
| رمز التحديث: |
20221213 |
| DOI: |
10.1021/acsbiomaterials.5b00369 |
| PMID: |
33429547 |
| قاعدة البيانات: |
MEDLINE |
Find this issue from the American Chemical Society